Additionally, osimertinib has been evaluated as a first-line treatment compared with first-generation EGFR-TKIs in EGFR mutation-positive advanced NSCLC patients, where it exhibited a longer PFS (18.9 months with osimertinib vs. 10.2 months with gefitinib or erlotinib), median duration of response (17.2 months with osimertinib vs. 8.5 months with gefitinib or erlotinib), and higher survival rates at 18 months (83% with osimertinib and 71% with gefitinib or erlotinib). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.